Mural Oncology (NASDAQ:MURA) reported quarterly losses of $(1.87) per share which beat the analyst consensus estimate of $(1.98) by 5.56 percent. This is a 39.09 percent increase over losses of $(3.07) per share from the same period last year.
Mural Oncology Q3 2024 GAAP EPS $(1.87) Beats $(1.98) Estimate, Cash, Cash Equivalents, And Marketable Securities Of $175.5M Are Expected To Fund Its Operations Into The Fourth Quarter Of 2025
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated